Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04184050
Title A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Harpoon Therapeutics
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | FRA | ESP

Facility Status City State Zip Country Details
Banner MD Anderson Cancer Center Gilbert Arizona 85234 United States Details
Mayo Clinic Arizona Phoenix Arizona 85054 United States Details
UC San Diego Moores Cancer Center La Jolla California 92093 United States Details
The University of Kansas Cancer Center Fairway Kansas 66205 United States Details
Roswell Park Comprehensive Cancer Center Buffalo New York 14263 United States Details
University of Rochester James P Wilmot Cancer Institute Rochester New York 14642 United States Details
OHSU Portland Oregon 97239 United States Details
University of Washington - Seattle Cancer Center Alliance Seattle Washington 98109 United States Details
Centre Hospitalier Universitaire De Nantes Nantes 44093 France Details
Centre Hospitalier Universitaire de Poitiers Poitiers 86021 France Details
Josep Carreras Leukaemia Research Institute Barcelona 08916 Spain Details
Hospital Universitario Fundacion Jimenez Diaz (UAM-FJD) Madrid 28040 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field